Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALAXY33: CD33-deleted HSCs and Gemtuzumab Ozogamicin in Relapsed AML
NCT05662904Phase 1Not yet recruiting
- Sponsor
- German Cancer Research Center
- Start
- Jan 2028
- Primary completion
- Jan 2029
- Modality
- Gene Silencing, CRISPR-Cas9, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tremtelectogene empogeditemcel in acute myeloid leukemia (AML), sponsored by German Cancer Research Center. Primary endpoints: Engraftment of gene edited CD34+HSC at Day 28, Dose-Limiting Toxicity at Day 90 and 1 more. Planned start Jan 2028; status: not yet recruiting.
02
Drugs
tremtelectogene empogeditemcel
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05662904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662904.